Literature DB >> 12552014

Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Bianca R Mothé1, Jason Weinfurter, Chenxi Wang, William Rehrauer, Nancy Wilson, Todd M Allen, David B Allison, David I Watkins.   

Abstract

Several HLA alleles are associated with attenuated human immunodeficiency virus disease progression. We explored the relationship between the expression of particular major histocompatibility complex (MHC) class I alleles and viremia in simian immunodeficiency virus SIV(mac)239-infected macaques. Of the common MHC class I alleles, animals that expressed Mamu-A*01 exhibited the best control of viral replication.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12552014      PMCID： PMC141082          DOI： 10.1128/jvi.77.4.2736-2740.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

Review 1.  Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.

Authors:  A K Sewell; D A Price; A Oxenius; A D Kelleher; R E Phillips
Journal:  Stem Cells       Date:  2000       Impact factor: 6.277

2.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

3.  Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.

Authors:  Bianca R Mothé; Helen Horton; Donald K Carter; Todd M Allen; Max E Liebl; Pam Skinner; Thorsten U Vogel; Sarah Fuenger; Kathy Vielhuber; William Rehrauer; Nancy Wilson; Genoveffa Franchini; John D Altman; Ashley Haase; Louis J Picker; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

5.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

Authors:  David H O'Connor; Todd M Allen; Thorsten U Vogel; Peicheng Jing; Ivan P DeSouza; Elizabeth Dodds; Edward J Dunphy; Cheri Melsaether; Bianca Mothé; Hiroshi Yamamoto; Helen Horton; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

7.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

Authors:  M Carrington; G W Nelson; M P Martin; T Kissner; D Vlahov; J J Goedert; R Kaslow; S Buchbinder; K Hoots; S J O'Brien
Journal:  Science       Date:  1999-03-12       Impact factor: 47.728

9.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

10.  Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.

Authors:  P J Goulder; M A Altfeld; E S Rosenberg; T Nguyen; Y Tang; R L Eldridge; M M Addo; S He; J S Mukherjee; M N Phillips; M Bunce; S A Kalams; R P Sekaly; B D Walker; C Brander
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307
View more
  127 in total

1.  Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities.

Authors:  Scott Southwood; Christopher Solomon; Ilka Hoof; Richard Rudersdorf; John Sidney; Bjoern Peters; Angela Wahl; Oriana Hawkins; William Hildebrand; Bianca R Mothé; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-01-28       Impact factor: 2.846

2.  Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques.

Authors:  Hiroshi Ishii; Miki Kawada; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Saori Matsuoka; Teiichiro Shiino; Akiko Takeda; Makoto Inoue; Akihiro Iida; Hiroto Hara; Tsugumine Shu; Mamoru Hasegawa; Taeko K Naruse; Akinori Kimura; Masafumi Takiguchi; Tetsuro Matano
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  SIV replication in the infected rhesus macaque is limited by the size of the preexisting TH17 cell compartment.

Authors:  Dennis J Hartigan-O'Connor; Kristina Abel; Koen K A Van Rompay; Bittoo Kanwar; Joseph M McCune
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

4.  Diversity of MHC class I genes in Burmese-origin rhesus macaques.

Authors:  Taeko K Naruse; Zhiyong Chen; Risa Yanagida; Tomoko Yamashita; Yusuke Saito; Kazuyasu Mori; Hirofumi Akari; Yasuhiro Yasutomi; Masaaki Miyazawa; Tetsuro Matano; Akinori Kimura
Journal:  Immunogenetics       Date:  2010-07-17       Impact factor: 2.846

5.  Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects.

Authors:  Yvonne M Mueller; Constantinos Petrovas; Duc H Do; Susan R Altork; Tracy Fischer-Smith; Jay Rappaport; John D Altman; Mark G Lewis; Peter D Katsikis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

6.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

7.  TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

Authors:  So-Yon Lim; Christa E Osuna; Peter T Hraber; Joe Hesselgesser; Jeffrey M Gerold; Tiffany L Barnes; Srisowmya Sanisetty; Michael S Seaman; Mark G Lewis; Romas Geleziunas; Michael D Miller; Tomas Cihlar; William A Lee; Alison L Hill; James B Whitney
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

8.  Identification of MHC class I sequences in four species of Macaca of China.

Authors:  Xiang Yan; Aixue Li; Lin Zeng; Yuhua Cao; Jianbin He; Longbao Lv; Lihua Sui; Huahu Ye; Junwen Fan; Xiaoxia Cui; Zhaozeng Sun
Journal:  Immunogenetics       Date:  2013-09-18       Impact factor: 2.846

9.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.